Annual CFO
-$7.86 M
-$629.70 K-8.71%
December 31, 2023
Summary
- As of February 7, 2025, MNPR annual cash flow from operations is -$7.86 million, with the most recent change of -$629.70 thousand (-8.71%) on December 31, 2023.
- During the last 3 years, MNPR annual CFO has fallen by -$3.20 million (-68.55%).
- MNPR annual CFO is now -557.82% below its all-time high of -$1.19 million, reached on December 31, 2016.
Performance
MNPR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.07 M
+$603.30 K+35.98%
September 30, 2024
Summary
- As of February 7, 2025, MNPR quarterly cash flow from operations is -$1.07 million, with the most recent change of +$603.30 thousand (+35.98%) on September 30, 2024.
- Over the past year, MNPR quarterly CFO has increased by +$581.90 thousand (+35.15%).
- MNPR quarterly CFO is now -251.85% below its all-time high of -$305.10 thousand, reached on June 30, 2017.
Performance
MNPR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$5.95 M
+$866.30 K+12.71%
September 30, 2024
Summary
- As of February 7, 2025, MNPR TTM cash flow from operations is -$5.95 million, with the most recent change of +$866.30 thousand (+12.71%) on September 30, 2024.
- Over the past year, MNPR TTM CFO has increased by +$1.29 million (+17.83%).
- MNPR TTM CFO is now -1810.63% below its all-time high of -$311.50 thousand, reached on March 31, 2017.
Performance
MNPR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
MNPR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.7% | +35.1% | +17.8% |
| 3 y3 years | -68.5% | +44.7% | +8.8% |
| 5 y5 years | -193.2% | +44.6% | -8.7% |
MNPR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -8.7% | at low | at high | +56.5% | at high | +25.2% |
| 5 y | 5-year | -160.4% | at low | -60.5% | +56.5% | -97.2% | +25.2% |
| alltime | all time | -557.8% | at low | -251.8% | +56.5% | -1810.6% | +25.2% |
Monopar Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.07 M(-36.0%) | -$5.95 M(-12.7%) |
| Jun 2024 | - | -$1.68 M(+1.3%) | -$6.82 M(-5.9%) |
| Mar 2024 | - | -$1.66 M(+7.1%) | -$7.24 M(-7.8%) |
| Dec 2023 | -$7.86 M(+8.7%) | -$1.55 M(-20.3%) | -$7.86 M(+3.2%) |
| Sep 2023 | - | -$1.94 M(-7.7%) | -$7.61 M(-2.7%) |
| Jun 2023 | - | -$2.10 M(-7.5%) | -$7.82 M(+11.2%) |
| Mar 2023 | - | -$2.27 M(+74.5%) | -$7.03 M(-2.7%) |
| Dec 2022 | -$7.23 M(-1.2%) | -$1.30 M(-39.4%) | -$7.23 M(-9.2%) |
| Sep 2022 | - | -$2.15 M(+63.9%) | -$7.96 M(+2.7%) |
| Jun 2022 | - | -$1.31 M(-46.9%) | -$7.75 M(-1.2%) |
| Mar 2022 | - | -$2.47 M(+21.4%) | -$7.85 M(+7.2%) |
| Dec 2021 | -$7.32 M(+56.9%) | -$2.03 M(+4.7%) | -$7.32 M(+12.1%) |
| Sep 2021 | - | -$1.94 M(+38.1%) | -$6.53 M(+10.9%) |
| Jun 2021 | - | -$1.41 M(-27.4%) | -$5.89 M(+7.5%) |
| Mar 2021 | - | -$1.94 M(+56.2%) | -$5.47 M(+17.4%) |
| Dec 2020 | -$4.66 M | -$1.24 M(-4.6%) | -$4.66 M(+14.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$1.30 M(+30.6%) | -$4.09 M(+20.2%) |
| Jun 2020 | - | -$995.50 K(-11.6%) | -$3.40 M(+8.1%) |
| Mar 2020 | - | -$1.13 M(+68.3%) | -$3.15 M(+4.3%) |
| Dec 2019 | -$3.02 M(+12.6%) | -$668.70 K(+9.0%) | -$3.02 M(+5.2%) |
| Sep 2019 | - | -$613.30 K(-17.1%) | -$2.87 M(+0.5%) |
| Jun 2019 | - | -$739.70 K(-25.7%) | -$2.85 M(-0.5%) |
| Mar 2019 | - | -$996.00 K(+91.8%) | -$2.87 M(+7.0%) |
| Dec 2018 | -$2.68 M(+2.0%) | -$519.20 K(-13.4%) | -$2.68 M(-10.0%) |
| Sep 2018 | - | -$599.60 K(-20.4%) | -$2.98 M(-16.7%) |
| Jun 2018 | - | -$752.90 K(-6.9%) | -$3.57 M(+14.3%) |
| Mar 2018 | - | -$808.80 K(-0.9%) | -$3.12 M(+18.9%) |
| Dec 2017 | -$2.63 M(+119.9%) | -$816.00 K(-31.7%) | -$2.63 M(+45.0%) |
| Sep 2017 | - | -$1.19 M(+291.6%) | -$1.81 M(+193.8%) |
| Jun 2017 | - | -$305.10 K(-2.1%) | -$616.60 K(+97.9%) |
| Mar 2017 | - | -$311.50 K | -$311.50 K |
| Dec 2016 | -$1.19 M | - | - |
FAQ
- What is Monopar Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Monopar Therapeutics?
- What is Monopar Therapeutics annual CFO year-on-year change?
- What is Monopar Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Monopar Therapeutics?
- What is Monopar Therapeutics quarterly CFO year-on-year change?
- What is Monopar Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Monopar Therapeutics?
- What is Monopar Therapeutics TTM CFO year-on-year change?
What is Monopar Therapeutics annual cash flow from operations?
The current annual CFO of MNPR is -$7.86 M
What is the all time high annual CFO for Monopar Therapeutics?
Monopar Therapeutics all-time high annual cash flow from operations is -$1.19 M
What is Monopar Therapeutics annual CFO year-on-year change?
Over the past year, MNPR annual cash flow from operations has changed by -$629.70 K (-8.71%)
What is Monopar Therapeutics quarterly cash flow from operations?
The current quarterly CFO of MNPR is -$1.07 M
What is the all time high quarterly CFO for Monopar Therapeutics?
Monopar Therapeutics all-time high quarterly cash flow from operations is -$305.10 K
What is Monopar Therapeutics quarterly CFO year-on-year change?
Over the past year, MNPR quarterly cash flow from operations has changed by +$581.90 K (+35.15%)
What is Monopar Therapeutics TTM cash flow from operations?
The current TTM CFO of MNPR is -$5.95 M
What is the all time high TTM CFO for Monopar Therapeutics?
Monopar Therapeutics all-time high TTM cash flow from operations is -$311.50 K
What is Monopar Therapeutics TTM CFO year-on-year change?
Over the past year, MNPR TTM cash flow from operations has changed by +$1.29 M (+17.83%)